https://www.selleckchem.com/products/rgfp966.html
generic competition related to introduction of a new version of branded glatiramer acetate was associated with $4.3 billion to $6.5 billion in excess spending. Extended market exclusivity from introducing a new version of an existing brand-name drug can yield manufacturer returns out of proportion to the level of investment or risk involved; more limited incentives could encourage incremental innovations to existing drugs at a lower societal cost. To investigate fluorescence lifetimes as well as spectral characteristics of drusen and RP
Me gusta
Comentario
Compartir
